Ocular Therapeutix (OCUL) Debt to Equity (2013 - 2026)

Ocular Therapeutix's Debt to Equity history runs 14 years deep, the most recent figure standing at $0.12 for Q1 2026.

• In Q1 2026, Debt to Equity fell 52.38% year-over-year to $0.12; the TTM figure through Mar 2026 stood at $0.12 (down 52.38% YoY), while the FY2025 annual figure was $0.11, down 49.81% from the prior year.
• Debt to Equity was $0.12 for Q1 2026 at Ocular Therapeutix, up from $0.11 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $8.29 in Q3 2023 to a low of $0.11 in Q4 2025.
• Historically, Debt to Equity has averaged $1.35 across 5 years, with a median of $0.27 in 2025.
• The sharpest annual moves came in 2023 and 2024: Debt to Equity jumped 1876.8% in 2023, then tumbled 97.68% in 2024.
• A 5-year view of Debt to Equity shows it stood at $0.71 in 2022, then advanced by 1.12% to $0.72 in 2023, then plunged by 69.91% to $0.22 in 2024, then sank by 49.81% to $0.11 in 2025, then grew by 13.65% to $0.12 in 2026.
• The last three Debt to Equity figures came in at $0.12 (Q1 2026), $0.11 (Q4 2025), and $0.27 (Q3 2025), per Business Quant data.